ONE MONTH INJECTION FOR OSTEOPOROSIS

描述（改编自应用程序）：骨质疏松症和佩吉特 疾病是两种最普遍的骨疾病。 骨质疏松症影响着美国2400多万人 而其受害者现在估计每年要花费70亿到100亿美元。 骨质疏松症每年导致130多万例骨折。佩吉特氏 疾病进展缓慢，可引起疼痛，溶骨性病变， 骨骼结构的严重畸形。骨质疏松症与佩吉特病 涉及骨生长和再吸收之间的不平衡;这两种疾病 可以用多肽激素有效治疗， 降钙素关注类固醇激素的副作用， 骨质疏松症的治疗迫使临床医生开降钙素 在欧洲，现在在美国。施用所述多肽 每日皮下或肌间注射。这种做法 由于不便和高发病率，患者接受度差 的不良反应。每月持续注射鲑鱼降钙素 可以提供更有吸引力的效率和 比现有的任何一种给药方法都方便。 拟定商业应用： 潜在的商业应用不可用。

DESCRIPTION (Adapted from the application): Osteoporosis and Paget's disease are two of the most widespread disorders of bone disease. Osteoporosis affects more than 24 million people in the United States and its victims now cost an estimated $7 to $10 billion per year. Osteoporosis contributes to over 1.3 million fractures per year. Paget's disease progresses slowly and can cause pain, osteolytic lesions, and gross deformities of bone structure. Osteoporosis and Paget's disease involve an imbalance between bone growth and resorption; both diseases can be treated effectively with polypeptide hormones known as calcitonins. Concern about the side effects of steroid hormones for the treatment of osteoporosis is forcing clinicians to prescribe calcitonin in Europe and now in the United States. The polypeptide is administered by daily subcutaneous or intermuscular injection. This practice is poorly accepted by patients because of inconvenience and high incidence of adverse reactions. A monthly sustained injection of salmon calcitonin could provide a much more attractive combination of efficiency and convenience than either of the existing methods of administration. PROPOSED COMMERCIAL APPLICATION: Potential commercial application not available.